Renalys Pharma Inc. completed a ¥6 billion (US$38.199 million) series A round that will enable it to complete a phase III trial for sparsentan for immunoglobulin A nephropathy (IgAN) in Japan. Tokyo-based Renalys in-licensed rights to sparsentan in January 2024 from Travere Therapeutics Inc. to develop the compound in Japan and 13 Asian countries to treat IgAN, a rare kidney disease.

Researchers have hypothesized that asparagine-linked glycosylation protein 3 homolog (ALG3) may be involved in the pathogenesis of preeclampsia by impacting the function of trophoblasts. Preeclampsia is still the leading cause of maternal and perinatal mortality and morbidity, but the mechanism behind it is still not clear.

Urogen Pharma Ltd. shares (NASDAQ:URGN) closed June 13 at $17.50, up $4.78, or 37%, on word of an 82.3% 12-month duration of response data by Kaplan-Meier estimate from its phase III Envision study with UGN-102. The finding was made in in low-grade, intermediate-risk, non-muscle invasive bladder cancer patients who achieved complete response at three months after the first instillation of the drug for intravesical solution.

The export of RNA from the cell nucleus is a key mechanism in the cell and during developmental stages. The pathway involving NTF2-related export protein 1 (NXT1) and nuclear RNA export factor 1 (NXF1) mediates bulk polyA mRNA through the nuclear pores.